Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 706 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 Coronavírus e COVID-19: o que as pessoas com câncer precisam saber June 22, 2020 Longer Duration of Treatment with ICIs Associated with a Higher Rate... March 5, 2025 Should People with Cancer and Cancer Survivors Get the Flu Vaccine? September 2, 2020 Load more HOT NEWS As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... Cancer in My Community: Encouraging Cancer Screening in Estonia EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20...
